Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

Welcome to the Money blog, Sky News' consumer and personal finance hub. Today: we take an overview of the mortgage market and ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

A MAJOR high street pharmacy has stopped selling Mounjaro amid a nationwide shortage of the popular fat jab. It comes just days after The Sun revealed the price of the ‘King Kong’ injection would ...

Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes ...

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.

This is all you need to know about the new weight loss jab 'Reta' that's said to be 3 times stronger than Ozempic.

Dr. Hussein Tawbi, who works for MD Anderson in Houston, said there are two things he hopes people take away from the story of Cowboys owner Jerry Jones beating cancer.

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for the long term. In a report released on August 13, Seamus Fernandez from Guggenheim maintained a Buy rating on Eli Lilly and ...